National Research Corp. (NRC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1157965,
    "name": "National Research Corp.",
    "stock_name": "National Research Corp.",
    "full_name": "National Research Corp.",
    "name_url": "stocks-analysis/national-research-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "16.32",
    "chg": 0.12,
    "chgp": "0.74%",
    "dir": 1,
    "prev_price": "16.20",
    "mcapval": "448.48",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Miscellaneous",
    "ind_code": 3370,
    "indexname": "S&P 500",
    "isin": "US6373722023",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "98.82 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/national-research-corp-1157965-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is National Research Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-national-research-corp-overvalued-or-undervalued-3637422",
        "imagepath": "",
        "date": "2025-10-21 12:01:57",
        "description": "As of 17 October 2025, the valuation grade for National Research Corp. moved from very expensive to expensive, indicating a slight improvement in perceived value. The company is currently considered overvalued based on its financial metrics. Key ratios include a P/E ratio of 17, an EV to EBITDA of 11.75, and a Price to Book Value of 14.27, which are all higher than its peer, Psychemedics Corp., which has a P/E of -8.09 and an EV to EBITDA of 14.32.\n\nIn comparison to the broader market, National Research Corp. has significantly underperformed, with a year-to-date return of -34.18% compared to the S&P 500's 13.30%. This stark contrast in performance further supports the conclusion that the stock is overvalued relative to its current financial standing and market conditions...."
      },
      {
        "title": "National Research Corp. Experiences Valuation Adjustment Amidst Market Performance Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/national-research-corp-valuation-grade-downgraded-from-very-expensive-to-expensive-3640824",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NationalResearc_valuationdot_3640824.png",
        "date": "2025-10-20 16:36:16",
        "description": "National Research Corp. has recently adjusted its valuation, with its stock price at $11.61. Over the past year, the company has seen a notable decline in performance, contrasting with the S&P 500. Key financial metrics indicate a strong position relative to peers, despite recent challenges in the market."
      },
      {
        "title": "Is National Research Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-national-research-corp-overvalued-or-undervalued-3634290",
        "imagepath": "",
        "date": "2025-10-20 12:19:47",
        "description": "As of 17 October 2025, the valuation grade for National Research Corp. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, with a P/E ratio of 17, a Price to Book Value of 14.27, and an EV to EBITDA of 11.75. In comparison, its peer Psychemedics Corp. has a P/E ratio of -8.09, highlighting a significant disparity in valuation between the two companies.\n\nGiven the current valuation ratios and the peer comparison, National Research Corp. is positioned at a higher valuation than its peers, suggesting it may not be an attractive investment at this time. While the company has a strong ROE of 82.18% and a solid ROCE of 38.17%, these figures do not sufficiently justify its expensive valuation. Additionally, the absence of return data makes it challenging to assess its performance against the S&P 500, bu..."
      },
      {
        "title": "Is National Research Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-national-research-corp-overvalued-or-undervalued-3631832",
        "imagepath": "",
        "date": "2025-10-19 11:57:25",
        "description": "As of 17 October 2025, the valuation grade for National Research Corp. has moved from very expensive to expensive, indicating a shift towards a less favorable assessment. The company appears to be overvalued based on its current metrics, with a P/E ratio of 17, a Price to Book Value of 14.27, and an EV to EBITDA of 11.75, all of which suggest that the stock is trading at a premium compared to its earnings and assets.\n\nIn comparison to its peers, National Research Corp. has a significantly higher P/E ratio of 17 compared to Psychemedics Corp.'s negative P/E of -8.09, and a higher EV to EBITDA ratio than the industry average. This suggests that investors may be paying too much for each dollar of earnings relative to similar companies. Furthermore, the stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -34.18% compared to the S&P 500's 13.30%, reinforcing th..."
      },
      {
        "title": "Is National Research Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-national-research-corp-technically-bullish-or-bearish-3545585",
        "imagepath": "",
        "date": "2025-09-20 19:14:34",
        "description": "As of 8 September 2025, the technical trend for National Research Corp. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. However, the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mildly bullish signal on the weekly chart but a mildly bearish signal on the monthly chart. The KST is mildly bearish weekly but mildly bullish monthly, and the Dow Theory presents a mildly bullish signal weekly but mildly bearish monthly. \n\nIn terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -9.92% versus the S&P 500's 12.22%, and a one-year return of -27.18% compared to 17.14% for the index...."
      },
      {
        "title": "Is National Research Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-national-research-corp-overvalued-or-undervalued-3542282",
        "imagepath": "",
        "date": "2025-09-20 17:49:12",
        "description": "As of 8 September 2025, the valuation grade for National Research Corp. has moved from expensive to very expensive, indicating a significant concern regarding its valuation. The company appears to be overvalued, especially when considering its P/E ratio of 17, which is notably lower than its peer Psychemedics Corp. at 24.89, and its EV to EBITDA ratio of 11.75, which is higher than Psychemedics' 14.32. Additionally, the Price to Book Value stands at 14.27, suggesting that the market is pricing the company at a substantial premium relative to its book value.\n\nIn terms of performance, National Research Corp. has underperformed against the S&P 500, with a year-to-date return of -9.92% compared to the index's 12.22%, and a staggering -68.24% return over the past five years versus the S&P 500's 96.61%. This stark contrast in returns further reinforces the notion that the stock is overvalued in the current market..."
      }
    ],
    "total": 11,
    "sid": "1157965",
    "stock_news_url": "https://www.marketsmojo.com/news/national-research-corp-1157965"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is National Research Corp. overvalued or undervalued?

2025-10-21 12:01:57

As of 17 October 2025, the valuation grade for National Research Corp. moved from very expensive to expensive, indicating a slight improvement in perceived value. The company is currently considered overvalued based on its financial metrics. Key ratios include a P/E ratio of 17, an EV to EBITDA of 11.75, and a Price to Book Value of 14.27, which are all higher than its peer, Psychemedics Corp., which has a P/E of -8.09 and an EV to EBITDA of 14.32. In comparison to the broader market, National Research Corp. has significantly underperformed, with a year-to-date return of -34.18% compared to the S&P 500's 13.30%. This stark contrast in performance further supports the conclusion that the stock is overvalued relative to its current financial standing and market conditions....

National Research Corp. Experiences Valuation Adjustment Amidst Market Performance Challenges

2025-10-20 16:36:16

National Research Corp. has recently adjusted its valuation, with its stock price at $11.61. Over the past year, the company has seen a notable decline in performance, contrasting with the S&P 500. Key financial metrics indicate a strong position relative to peers, despite recent challenges in the market.

Is National Research Corp. overvalued or undervalued?

2025-10-20 12:19:47

As of 17 October 2025, the valuation grade for National Research Corp. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, with a P/E ratio of 17, a Price to Book Value of 14.27, and an EV to EBITDA of 11.75. In comparison, its peer Psychemedics Corp. has a P/E ratio of -8.09, highlighting a significant disparity in valuation between the two companies. Given the current valuation ratios and the peer comparison, National Research Corp. is positioned at a higher valuation than its peers, suggesting it may not be an attractive investment at this time. While the company has a strong ROE of 82.18% and a solid ROCE of 38.17%, these figures do not sufficiently justify its expensive valuation. Additionally, the absence of return data makes it challenging to assess its performance against the S&P 500, bu...

Is National Research Corp. overvalued or undervalued?

2025-10-19 11:57:25

As of 17 October 2025, the valuation grade for National Research Corp. has moved from very expensive to expensive, indicating a shift towards a less favorable assessment. The company appears to be overvalued based on its current metrics, with a P/E ratio of 17, a Price to Book Value of 14.27, and an EV to EBITDA of 11.75, all of which suggest that the stock is trading at a premium compared to its earnings and assets. In comparison to its peers, National Research Corp. has a significantly higher P/E ratio of 17 compared to Psychemedics Corp.'s negative P/E of -8.09, and a higher EV to EBITDA ratio than the industry average. This suggests that investors may be paying too much for each dollar of earnings relative to similar companies. Furthermore, the stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -34.18% compared to the S&P 500's 13.30%, reinforcing th...

Is National Research Corp. technically bullish or bearish?

2025-09-20 19:14:34

As of 8 September 2025, the technical trend for National Research Corp. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. However, the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mildly bullish signal on the weekly chart but a mildly bearish signal on the monthly chart. The KST is mildly bearish weekly but mildly bullish monthly, and the Dow Theory presents a mildly bullish signal weekly but mildly bearish monthly. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -9.92% versus the S&P 500's 12.22%, and a one-year return of -27.18% compared to 17.14% for the index....

Is National Research Corp. overvalued or undervalued?

2025-09-20 17:49:12

As of 8 September 2025, the valuation grade for National Research Corp. has moved from expensive to very expensive, indicating a significant concern regarding its valuation. The company appears to be overvalued, especially when considering its P/E ratio of 17, which is notably lower than its peer Psychemedics Corp. at 24.89, and its EV to EBITDA ratio of 11.75, which is higher than Psychemedics' 14.32. Additionally, the Price to Book Value stands at 14.27, suggesting that the market is pricing the company at a substantial premium relative to its book value. In terms of performance, National Research Corp. has underperformed against the S&P 500, with a year-to-date return of -9.92% compared to the index's 12.22%, and a staggering -68.24% return over the past five years versus the S&P 500's 96.61%. This stark contrast in returns further reinforces the notion that the stock is overvalued in the current market...

View All News